Why Aurinia Pharmaceuticals Stock Is Skyrocketing Today

  • Summary:


    Aurinia Pharmaceuticals (NASDAQ:AUPH), a late-stage developmental biotech, saw its shares rocket higher in after-hours trading Wednesday by a whopping 125%. The biotech's shares took flight in response to positive late-stage trial results for the experimental lupus nephritis drug candidate voclosporin. Lupus nephritis, in layman's terms, is a swelling of the kidneys caused by systemic lupus erythematosus.

    The big-ticket item is that voclosporin reportedly produced significantly higher kidney response rates than placebo when used in combination with mycophenolate and low-dose corticosteroids in this pivota ...



    Read Full News: https://www.fool.com/investing/2019/12/04/why-aurinia-pharmaceuticals-inc-stock-is-skyrocket.aspx

Log in to reply